Last Updated : April 18, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort descending | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Keytruda and Lenvima | pembrolizumab and lenvatinib | Advanced endometrial cancer | Withdrawn | |||
| Kineret | anakinra | Still's disease | Withdrawn | |||
| TBC | daprodustat | Anemia due to chronic kidney disease | Withdrawn | |||
| Alsitek | masitinib mesylate | Amyotrophic lateral sclerosis (ALS) | Suspended | |||
| TBC | abaloparatide | Osteoporosis, postmenopausal women | Withdrawn | |||
| TBC | tirzepatide | Diabetes mellitus, type 2 | Cancelled | |||
| TBC | ferumoxytol | Iron deficiency anemia | Withdrawn | |||
| TBC | filgotinib | Arthritis, Rheumatoid | Withdrawn | |||
| TBC | etonogestrel | Prevention of pregnancy | Withdrawn | |||
| Tecentriq | Atezolizumab | Withdrawn |
Last Updated : April 18, 2024